YMAB — Y-mAbs Therapeutics Share News
0.000.00%
Last trade - 00:00- $390.32m
- $328.02m
- $87.69m
Y-mAbs Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Y-mAbs Therapeutics' Q2 revenue falls 14%
Brief: Serb Pharmaceuticals Agrees To Acquire Y-Mabs Therapeutics
Y-mAbs Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Y-mAbs Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Y-mAbs Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Y-mAbs Therapeutics Inc Enters Equity Distribution Agreement With Oppenheimer
U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth
Y-mAbs Therapeutics falls following gloomy 2025 revenue forecast
Y-mAbs Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Y-mAbs Reports Fourth Quarter 2024 Financial Results
Y-mAbs Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Y-mAbs Therapeutics falls on plans to create two business units
Brief: Y-Mabs Appoints Doug Gentilcore As Head Of Danyelza Unit
Y-mAbs Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Y-mAbs Reports Q3 2024 Financial Results And Recent Corporate Developments
Brief: Y-mAbs Therapeutics Q3 Net Income USD -7 Million Vs. IBES Estimate USD -7.42 Million
Y-mAbs Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Y-mAbs Therapeutics Q2 Net Income USD -9.2 Million Vs. IBES Estimate USD -6.31 Million